Protagonist Therapeutics, Inc. (PTGX)
- Previous Close
31.94 - Open
32.02 - Bid 30.67 x 100
- Ask 30.79 x 400
- Day's Range
30.64 - 32.14 - 52 Week Range
13.72 - 33.34 - Volume
437,118 - Avg. Volume
559,049 - Market Cap (intraday)
1.803B - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
12.10 - EPS (TTM)
2.54 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.80
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
www.protagonist-inc.comRecent News: PTGX
Performance Overview: PTGX
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTGX
Valuation Measures
Market Cap
1.80B
Enterprise Value
1.48B
Trailing P/E
12.10
Forward P/E
23.64
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.86
Price/Book (mrq)
3.22
Enterprise Value/Revenue
4.70
Enterprise Value/EBITDA
9.74
Financial Highlights
Profitability and Income Statement
Profit Margin
51.47%
Return on Assets (ttm)
21.38%
Return on Equity (ttm)
41.75%
Revenue (ttm)
314.95M
Net Income Avi to Common (ttm)
162.11M
Diluted EPS (ttm)
2.54
Balance Sheet and Cash Flow
Total Cash (mrq)
322.64M
Total Debt/Equity (mrq)
0.08%
Levered Free Cash Flow (ttm)
-154.68M
Research Analysis: PTGX
Company Insights: PTGX
PTGX does not have Company Insights